Mark J. Ratain, MDLeon O. Jacobson Professor of MedicineDirector, Center for Personalized TherapeuticsAssociate Director for Clinical Sciences, Comprehensive Cancer CenterDr. Mark Ratain is an expert in the use of investigational agents to treat advanced solid tumors. He also has a special interest in pharmacogenetics -- the study of how genetic variation affects the body's response to medications. Dr. Ratain’s research focuses on the development of new oncology drugs, and developing diagnostic tests in order to create individualized anticancer therapies based on each person’s genetic makeup. He is an international leader in phase I clinical trials, pharmacogenetics, and clinical trial methodology. He has more than 235 original publications, leads the University of Chicago’s phase I oncology trials program, and serves as director of the Center for Personalized Therapeutics. Dr. Ratain is also co-chair of the Pharmacogenomics of Anticancer Agents Research (PAAR) Group, which brings together teams of experts from across the nation to investigate advancements in pharmacogenomics. In 2011, Dr. Ratain was awarded the Translational Research Professorship by the American Society for Clinical Oncology's (ASCO) Conquer Cancer Foundation, and named an honorary fellow by the American College of Clinical Pharmacology. Practice LocationsUniversity of Chicago Medical Center
Center for Advanced Medicine
Year Started Practice1986 Board CertificationsClinical Pharmacology
Medical SchoolYale University School of Medicine, New Haven, CT Internship and ResidencyJohns Hopkins University, Baltimore, MD FellowshipUniversity of Chicago Medical Center MembershipsAmerican Association for Cancer Research
Language SpokenEnglish mratain@medicine.bsd.uchicago.edu Office Phone(773) 702-6149 Office Fax(773) 702-3969 Office Postal AddressMark J. Ratain, MD
|
Clinical Interests
Request an appointment online
Read More About Dr. RatainIn 2011, Dr. Ratain was awarded the Translational Research Professorship by the American Society for Clinical Oncology's (ASCO) Conquer Cancer Foundation, and named an honorary fellow by the American College of Clinical Pharmacology. In this ABC7 news story, Dr. Ratain discusses genetic code mapping and the 1200 Patients Project. Dr. Ratain earned a prestigious grant renewal, which extended his PAAR Group research investigation of unique patient dosing based on genetic factors. Read more about a study, led by Dr. Ratain, designed to determine a drug's effectiveness in shrinking advanced kidney tumors. Selected PublicationsView a partial list of Dr. Ratain's publications through the National Library of Medicine's PubMed online database. |



